An observational study in Huntington Disease, sponsored by CHDI Foundation, Inc.. Status unknown at 10 sites in 5 countries. Open to participants aged 18 Years to 63 Years. Per ClinicalTrials.gov, last updated 2022-09-23.
Sponsored by CHDI Foundation, Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Huntington Disease by CHDI Foundation, Inc. — 2 open to participants now, 2 under way, none of them phase 3. Huntington Disease · CHDI Foundation, Inc..
Among the 11 studies in Huntington Disease by CHDI Foundation, Inc., this one is one of 3 that started in 2020, is one of 7 observational ones, and was the 10th registered.
293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.
Browse Huntington Disease studies →2 of the 11 studies in Huntington Disease by CHDI Foundation, Inc. are open now, in 12 countries. Recruiting first, the newest first:
CHDI Foundation, Inc. · Sites in Belgium
Ages 18–64 · Healthy volunteers
CHDI Foundation, Inc. · Sites in United States, Argentina, Australia and 17 more countries
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 63 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2020.
This study's enrollment of 70 is below the median of 90 across 82 observational studies indexed under Huntington Disease.
Median enrollment 36 across the 4 interventional studies, 233 across the 7 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
CHDI Foundation, Inc. is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Huntington Disease by CHDI Foundation, Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
SHIELD HD is an international, multisite, prospective, longitudinal cohort natural history study to assess the natural history of HD and its biomarkers that are associated with modulation of the number of cytosine-adenine-guanine (CAG) repeats in the mutant Huntingtin (HTT) gene.
Approximately 60 patients will be enrolled into the study and followed for up to 24 months at clinical sites in North America and Europe.
The results of this study will inform assessments for a future interventional treatment trial.
The rationale for this study is to obtain longitudinal information related to Somatic Instability and DNA damage response genes in HDGECs at various stages of the disease. Established assessments of disease progression will also be recorded.
Huntington disease (HD), genetically confirmed by direct DNA testing, either obtained previously or performed at Screening
Key Inclusion Criteria
Patients who meet all of the following criteria will be eligible to participate in the study:
Key Exclusion Criteria
Patients who meet any of the following criteria will be excluded from participation in the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DDR gene expression
To assess deoxyribonucleic acid (DNA) damage repair (DDR) gene expression in accessible biofluids and disease trajectories for established and novel biomarkers and clinical outcomes.
Time frame: 2 years
Compare rates of change in biomarkers for disease progression
To compare the rates of change for different outcomes and cytosine adenine guanine (CAG) age product (CAP) Scores.
Time frame: 2 years
Additional biomarkers to be examined
The exploratory objectives of this study are to be determined and may include the examination of additional biomarkers present in CSF, plasma, and whole blood, including but not limited to mutant HTT (mHTT) protein, cytokines, and others, as well as clinical markers of progression.
Time frame: 2 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started May 2020 (actual). Primary completion is estimated for Apr 2023, 35 months after the start.
Of 34 observational studies under Huntington Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 34. This study's planned 35 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CHDI Foundation, Inc.